Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in generalized AChR-antibody positive myasthenia gravis with single-cell B-cell phenotyping
2024-518939-12-00Phase 3Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in myasthenia gravis (MG) comparing Rituximab plus prednisone with Placebo plus prednisone (2 arms). Primary endpoint: Change from baseline in Quantitative Myasthenia Gravis Score. Planned start Nov 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-518939-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518939-12-00.